{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T22:57:17Z","timestamp":1766012237236},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.7104","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T22:15:20Z","timestamp":1480544120000},"page":"3495-3497","source":"Crossref","is-referenced-by-count":9,"title":["Symptomatic Acute Pancreatitis Induced by Nilotinib: A Report of Two Cases"],"prefix":"10.2169","volume":"55","author":[{"given":"Toshiki","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Hematology, Gifu Prefectural Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University, Japan"},{"name":"Department of Transfusion Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Seishima","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Gifu University, Japan"},{"name":"Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14: 5325-5331, 2008.","DOI":"10.1158\/1078-0432.CCR-08-0308"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551, 2006.","DOI":"10.1056\/NEJMoa055104"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111: 1834-1839, 2008.","DOI":"10.1182\/blood-2007-04-083196"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph<sup>+<\/sup> chronic myeloid leukemia. Blood 114: 4933-4938, 2009.","DOI":"10.1182\/blood-2009-07-232595"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tojo A, Usuki K, Urabe A, et al. A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph<sup>+<\/sup> CML or relapsed\/refractory Ph<sup>+<\/sup> ALL. Int J Hematol 89: 679-688, 2009.","DOI":"10.1007\/s12185-009-0327-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zhou L, Meng F, Yin O, et al. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther 31: 1568-1575, 2009.","DOI":"10.1016\/j.clinthera.2009.07.016"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259, 2010.","DOI":"10.1056\/NEJMoa0912614"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 5: 648-661; quiz 644, 2007.","DOI":"10.1016\/j.cgh.2006.11.023"},{"key":"9","unstructured":"9. Jones MR, Hall OM, Kaye AM, Kaye AD. Drug-induced acute pancreatitis: a review. Ochsner J 15: 45-51, 2015."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gan SI, Edwards AL, Symonds CJ, Beck PL. Hypertriglyceridemia-induced pancreatitis: a case-based review. World J Gastroenterol 12: 7197-7202, 2006.","DOI":"10.3748\/wjg.v12.i44.7197"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations. J Clin Endocrinol Metab 85: 3085-3088, 2000.","DOI":"10.1210\/jc.85.9.3085"},{"key":"12","unstructured":"12. PMDA. nilotinib drug information sheet. https:\/\/www.pmda.go.jp\/"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/23\/55_55.7104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:54:44Z","timestamp":1498366484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/23\/55_55.7104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":12,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.7104","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}